Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1

di Aspinall, Claire F., Zheleva, Daniella, Tighe, Anthony, Taylor, Stephen S.
Pubblicato in Oncotarget (2015)

Aurora kinase inhibitors: Progress towards the clinic

di Kollareddy, Madhu, Zheleva, Daniella, Dzubak, Petr, Brahmkshatriya, Pathik Subhashchandra, Lepsik, Martin, Hajduch, Marian
Pubblicazione 2012

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

di Chantkran, Wittawat, Hsieh, Ya-Ching, Zheleva, Daniella, Frame, Sheelagh, Wheadon, Helen, Copland, Mhairi
Pubblicato in Cell Death Discov (2021)

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

di Chantkran, Wittawat, Hsieh, Ya-Ching, Zheleva, Daniella, Frame, Sheelagh, Wheadon, Helen, Copland, Mhairi
Pubblicato in Cell Death Discov (2021)

Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design

di Kontopidis, George, Wu, Su-Ying, Zheleva, Daniella I., Taylor, Paul, McInnes, Campbell, Lane, David P., Fischer, Peter M., Walkinshaw, Malcolm D.
Pubblicazione 2005

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

di Frame, Sheelagh, Saladino, Chiara, MacKay, Craig, Atrash, Butrus, Sheldrake, Peter, McDonald, Edward, Clarke, Paul A., Workman, Paul, Blake, David, Zheleva, Daniella
Pubblicato in PLoS One (2020)

Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma

di Noonan, Janis J., Jarzabek, Monika, Lincoln, Frank A., Cavanagh, Brenton L., Pariag, Arhona R., Juric, Viktorija, Young, Leonie S., Ligon, Keith L., Jahns, Hanne, Zheleva, Daniella, Prehn, Jochen H. M., Rehm, Markus, Byrne, Annette T., Murphy, Brona M.
Pubblicato in Cancers (Basel) (2019)

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

di Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E., Licciardello, Marco P., Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M., Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S., Christova, Rossitza, Boysen, Gunther, Richards, Mark W., Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A., De Bono, Johann, Gray, Nathanael S., Blagg, Julian, Robinson, Simon P., Eccles, Suzanne A., Zheleva, Daniella, Bradner, James E., Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y., Chesler, Louis
Pubblicato in J Clin Invest (2020)